Evolving Landscape of Treatment for Hepatocellular Carcinoma with Multi-Targeted Tyrosine Kinase Inhibitors and Immunotherapy – Enduring Webcast

Description

Program Description

---

This webcast is intended to improve care of patients with hepatocellular carcinoma (HCC) by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Intended Audience

---

This webcast is designed to meet the educational needs of hematologists/oncologists, hepatologists, interventional radiologist, gastroenterologists, transplant surgeons, pathologists and other health care professionals who diagnose, treat, and manage patients with HCC.

Commercial Supporter

---

Supported by Merck Sharpe & Dohme Corp., and Eisai, Inc